Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
NUM
Sort by
Title
P
Favorite
059
Perioperative Antibiotic Prophylaxis in Paediatric Cardiac Surgery – is One Day Sufficient to Prevent Surgical Site Infections?
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
017
Pharmacist Administered Parenteral Medications: A Descriptive Study of a Novel Inpatient Training Program
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
152
Pharmacoeconomic Analysis of Therapeutic Regimens Used for Treatment of Psoriasis in India
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
107
Pharmacokinetic & Immunogenicity Results from the China Cohort of the MAJESTEC-1 Study of Teclistamab for Relapsed/refractory Multiple Myeloma
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
068
Pharmacokinetic Analyses & Population Pharmacokinetic Modeling of Maplirpacept in Patients With Newly Diagnosed Acute Myeloid Leukemia
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
114
Pharmacokinetic Characterization of Flotetuzumab in Pediatric Patients With Refractory/Relapsed Acute Myeloid Leukemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
109
Pharmacokinetic Comparison Between Fixed-dose Combination of Rosuvastatin/Ezetimibe 2.5/10 mg & the Coadministration of Individual Formulations in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
108
Pharmacokinetic Comparison of Ezetimibe/Rosuvastatin/Telmisartan Fixed-dose Combination vs Coadministration of Separate Treatments
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
060
Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
051
Pharmacokinetically-Guided Dosing of Fludarabine for Lymphodepletion in CAR T-cell Therapy: A Clinical Trial Simulation Study
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
140
Pharmacokinetic-Pharmacodynamic Analysis of Cytokines in First-in-Human Phase 1 Dose Escalation Study of the MALT-1 Inhibitor, SGR-1505, in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
157
Pharmacokinetics & Exposure-Response Analyses of Revumenib Support Dosing in a Broad Population of Patients With Relapsed/Refractory Acute Leukemias
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
042
Pharmacokinetics & Exposure-safety Analyses Across Tumor Types for Ifinatamab Deruxtecan (I-DXd) in the First-in-Human Study IDeate-Pantumor01 (DS7300-A-J101)
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
072
Pharmacokinetics & Pharmacodynamics of Milvexian After Administration Every 12 Hours in Healthy Subjects
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
112
Pharmacokinetics & Safety of Teclistamab Administered in the Arm or Thigh of Patients With Relapsed/Refractory Multiple Myeloma in MajesTEC-1
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
064
Pharmacokinetics of 6-diazo-5-oxo-L-norleucine (DON) in Malawian Healthy Adults & Adults With Uncomplicated Malaria
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
162
Pharmacokinetics of DYP688 in Patients With Metastatic Uveal Melanoma & Other GNAQ/11 Mutant Melanomas
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
154
Pharmacokinetics of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
083
Pharmacokinetics of Tenofovir Alafenamide, Emtricitabine & Dolutegravir in a Patient on Peritoneal Dialysis
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
090
Pharmacokinetics of Tetrahydrocannabinol in Infants Exposed to Breastmilk from Recreational Cannabis Users
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
159
Pharmacokinetics, Pharmacodynamics & Safety of Budigalimab, An Anti-PD-1 Monoclonal Antibody, in People Living With HIV-1
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
078
Pharmacokinetics, Pharmacodynamics & Safety of Rusfertide, A Hepcidin Mimetic, in Subjects With Hepatic Impairment & in Subjects With Renal Impairment
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
113
Pharmacokinetics, Safety & Tolerability of GS-1427, a Pro-drug of a Potent & Selective Small-Molecule α4β7 Integrin Inhibitor, in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
110
Phase 1, Single-Center, Randomized, Placebo-Controlled, Partially Blinded, Single Ascending Dose Study on the Effects of Troriluzole on corrected QT in Healthy Subjects
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
026
Phase I Open Label Study to Evaluate the Effects of Savolitinib on the Pharmacokinetics of P-gp, OATP1B1/3, OCT2, MATE1/2K & OAT1/3 Substrates in Healthy Volunteers
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
127
Phase I Open Label Study to Evaluate the Effects of Strong CYP1A2 Inhibitor on Savolitinib Pharmacokinetics in Healthy Volunteers
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
029
Physiologically-based Pharmacokinetic Modeling of a Novel HER3-Targeted Antibody-Drug Conjugate, Patritumab Deruxtecan to Assess Pharmacokinetic Drug-Drug Interaction
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
145
Physiologically-based Pharmacokinetic Models of Opioid in Pregnancy, Maternal-Fetal, Pediatrics & Breastfeeding Mothers: A Systematic Literature Review
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
135
Population Kinetic-Pharmacodynamic Modeling of Multiple Lipid Biomarker Responses to Zodasiran in Patients With Mixed Dyslipidemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
041
Population Modeling Framework With Adaptive Dosing for Optimizing Clinical Utility of Compounds in Development for Treatment of Solid Tumors
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
070
Population Pharmacokinetic & Exposure-Response Analyses for the Phase 3 PhALLCON Study of Ponatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
066
Population Pharmacokinetic Analysis of Cenobamate
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
048
Population Pharmacokinetic and Exposure-response Analyses of anti-BDCA2 Antibody Litifilimab Support Its Clinical Benefit for Cutaneous Lupus Erythematosus
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
144
Population Pharmacokinetic Model for Tulisokibart in Healthy Participants
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
136
Population Pharmacokinetics & Pharmacodynamics of Pegozafermin, a Novel GlycoPEGylated FGF21, in a Phase 2 Study in Severe Hypertriglyceridemia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
069
Population Pharmacokinetics of Bictegravir in Pregnant & Postpartum Persons Living With HIV
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
045
Population Pharmacokinetics of GB-5001, a Long-acting Intramuscular Injection of Donepezil, in Healthy Participants
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
075
Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
153
Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02385 in Patients With Select Advanced Malignancies
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
Favorite
035
Potential Epigenetic Opioid-Chemotherapy Drug Interactions
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
063
Preclinical & Clinical Pharmacokinetics of JNJ-75220795, A siRNA Therapeutic Targeting
PNPLA3
, for Metabolic-associated Steatohepatitis
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
085
Predicting Metoprolol Exposure-Response in Pregnant Population Using Physiologically-based Pharmacokinetic Modeling
Sunday, September 8, 2024
5:00 PM – 7:00 PM
ET
Favorite
125
Pregabalin-codeine-disease Interactions in Patients With Acute Herpetic or Postherpetic Neuralgia
Monday, September 9, 2024
5:00 PM – 7:00 PM
ET
